Does the FDA link HRT to dementia risk

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

The FDA does not say that hormone therapy causes dementia in all women. According to FDA-approved prescribing information for systemic estrogens, the FDA includes a warning that in studies of women aged 65 and older, certain forms of HRT were associated with a higher risk of dementia, and this warning appears on product labels. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

What the FDA actually says

According to FDA-approved prescribing information for systemic estrogens, the FDA bases its warning on a large study called the Women's Health Initiative Memory Study (WHIMS). This study looked at women who were 65 to 79 years old when they started HRT. In that specific age group:

• Estrogen plus progestin (CEE+MPA): Women had a higher risk of being diagnosed with dementia compared with those taking placebo.
• Estrogen alone (CEE): The dementia risk was not clearly increased by itself, but there was a higher rate of cognitive problems when dementia and milder impairment were looked at together. Because of this, the FDA includes a similar warning.

Because these findings applied only to women who were already 65 or older at the time they began therapy, according to FDA-approved prescribing information for systemic estrogens, the FDA requires language warning about dementia risk for both estrogen-only and estrogen-progestin products in that age group.

What the FDA does not say

• It does not say HRT causes dementia in younger menopausal women.
• It does not say HRT raises dementia risk when started around the time of menopause (typically the late 40s to mid‑50s).
• It does not apply these findings to transdermal forms specifically; the studies used oral formulations.

Why age matters

Brains change with age. According to the WHI, women in the WHIMS study were many years beyond natural menopause when they began hormones. Starting HRT after age 65 may not offer the same benefits or safety profile as starting near menopause. This is why most menopause experts, including those at NAMS, consider the WHIMS dementia signal a finding about late initiation, not about appropriate use earlier in the menopausal transition.

Bottom line

According to FDA-approved prescribing information for systemic estrogens, hormone therapy taken by women 65 and older was associated with an increased risk of dementia in one major study. The FDA does not consider HRT a dementia risk for healthy women who start treatment around the usual menopausal years. Decisions should focus on your age, symptoms, health history, and the specific type and route of hormone therapy, in consultation with a qualified prescriber.

Important note: According to the FDA-approved prescribing information for systemic estrogens, products in this class carry a boxed warning regarding probable dementia in postmenopausal women age 65 and older based on Women's Health Initiative Memory Study (WHIMS) data. Clinical decisions about hormone therapy and cognitive risk should be made with a qualified prescriber.